Comparación de los modelos SCORE y REGICOR para el cálculo del riesgo cardiovascular en sujetos sin enfermedad cardiovascular atendidos en un centro de salud de Barcelona

Díez, José Miguel Baena; García, José Luis del Val; Gaetgens, Luis Héctor Salas; Pérez, Ricard Sánchez; Vaques, Eva Altes; Martínez, Bibiana Deixens; Corominas, M; Casillas, Dynaida Katia Núñez

doi:10.1590/s1135-57272005000400003

Cited by 41 publications

(22 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Comparisons between SCORE and REGICOR did not disclose that one of them might be better than the other in establishing the CV risk in Spanish individuals without rheumatic diseases [33-37]. In the present study, neither mSCORE nor mREGICOR were shown to be effective in the stratification of the CV risk of Spanish RA patients.…”

Section: Discussioncontrasting

confidence: 70%

SCORE and REGICOR function charts underestimate the cardiovascular risk in Spanish patients with rheumatoid arthritis

et al. 2013

View full text Add to dashboard Cite

IntroductionOur objective was to determine which one of the two function charts available in Spain to calculate cardiovascular (CV) risk, Systematic COronary Risk Evaluation (SCORE) or Framingham-REgistre GIroní del COR (REGICOR), should be used in patients with rheumatoid arthritis (RA).MethodsA series of RA patients seen over a one-year period without history of CV events were assessed. SCORE, REGICOR, modified (m)SCORE and mREGICOR according to the European League Against Rheumatism (EULAR) recommendations were applied. Carotid ultrasonography (US) was performed. Carotid intima-media thickness (cIMT) > 0.90 mm and/or carotid plaques were used as the gold standard test for severe subclinical atherosclerosis and high CV risk (US+). The area under the receiver operating curves (AUC) for the predicted risk for mSCORE and mREGICOR were calculated according to the presence of severe carotid US findings (US+).ResultsWe included 370 patients (80% women; mean age 58.9 ± 13.7 years); 36% had disease duration of 10 years or more; rheumatoid factor (RF) and/or anticyclic citrullinated peptide (anti-CCP) were positive in 68%; and 17% had extra-articular manifestations. The EULAR multiplier factor was used in 122 (33%) of the patients. The mSCORE was 2.16 ± 2.49% and the mREGICOR 4.36 ± 3.46%. Regarding US results, 196 (53%) patients were US+. The AUC mSCORE was 0.798 (CI 95%: 0.752 to 0.844) and AUC mREGICOR 0.741 (95% CI; 0.691 to 0.792). However, mSCORE and mREGICOR failed to identify 88% and 91% of US+ patients. More than 50% of patients with mSCORE ≥1% or mREGICOR >1% were US+.ConclusionsNeither of these two function charts was useful in estimating CV risk in Spanish RA patients.

show abstract

Section: Discussioncontrasting

confidence: 70%

SCORE and REGICOR function charts underestimate the cardiovascular risk in Spanish patients with rheumatoid arthritis

et al. 2013

View full text Add to dashboard Cite

show abstract

“…9 In Spain, there are only a few studies designed to describe CVR at the population level. [10][11][12][13][14][15][16][17] These studies are either limited by their sample size, or focused on specific groups with at least one of the classical cardiovascular risk factors (CVRF), or performed in specific regions that may not be representative of the entire country. Furthermore, none of these surveys included high-density lipoprotein cholesterol (HDL-C) in the estimation of CVR.…”

Section: Introductionmentioning

confidence: 99%

Estimating Cardiovascular Risk in Spain by the European Guidelines on Cardiovascular Disease Prevention in Clinical Practice

Amor

Masana

Soriguer

et al. 2015

Revista Española de Cardiología (English Edition)

View full text Add to dashboard Cite

“…Systolic and diastolic blood pressure (SBP and DBP) were measured twice with validated and calibrated electronic sphygmomanometers after 5 minutes rest. Cardiovascular risk was calculated according to Framingham-Regicor [13,14] predictive equations calibrated for Girona (Spain) and according to the Score [13] project for European population at low risk. Framingham-Regicor risk tables have been adapted and validated with data from the population of Girona (Spain) in the VERIFICA study [14,15].…”

Section: Methodsmentioning

confidence: 99%

Screening premorbid metabolic syndrome in community pharmacies: a cross-sectional descriptive study

Via-Sosa¹,

Toro

Travé

et al. 2014

BMC Public Health

View full text Add to dashboard Cite

BackgroundPremorbid metabolic syndrome (pre-MetS) is a cluster of cardiometabolic risk factors characterised by central obesity, elevated fasting glucose, atherogenic dyslipidaemia and hypertension without established cardiovascular disease or diabetes. Community pharmacies are in an excellent position to develop screening programmes because of their direct contact with the population.The main aim of the study was to determine the prevalence of pre-MetS in people who visited community pharmacies for measurement of any of its five risk factors to detect the presence of other risk factors. The secondary aims were to study the presence of other cardiovascular risk factors and determine patients’ cardiovascular risk.MethodsCross-sectional, descriptive, multicentre study. Patients meeting selection criteria aged between 18 and 65 years who visited participating community pharmacies to check any of five pre-MetS diagnostic factors were included.The study involved 23 community pharmacies in Catalonia (Spain). Detection criteria for pre-MetS were based on the WHO proposal following IDF and AHA/NHBI consensus. Cardiovascular risk (CVR) was calculated by Regicor and Score methods. Other variables studied were smoking habit, physical activity, body mass index (BMI), and pharmacological treatment of dyslipidemia and hypertension. The data were collected and analysed with the SPSS programme. Comparisons of variables were carried out using the Student’s T-test, Chi-Squared test or ANOVA test. Level of significance was 5% (0.05).ResultsThe overall prevalence of pre-MetS was 21.9% [95% CI 18.7-25.2]. It was more prevalent in men, 25.5% [95% CI 22.1-28.9], than in women, 18.6% [95% CI 15.5-21.7], and distribution increased with age. The most common risk factors were high blood pressure and abdominal obesity. About 70% of people with pre-MetS were sedentary and over 85% had a BMI ≥25 Kg/m2. Some 22.4% had two metabolic criteria and 27.2% of patients with pre-MetS had no previous diagnosis.ConclusionsThe prevalence of pre-MetS in our study (21.9%) was similar to that found in other studies carried out in Primary Care in Spain. The results of this study confirm emergent cardiometabolic risk factors such as hypertension, obesity and physical inactivity.Our study highlights the strategic role of the community pharmacy in the detection of pre-MetS in the apparently healthy population.

show abstract

Comparación de los modelos SCORE y REGICOR para el cálculo del riesgo cardiovascular en sujetos sin enfermedad cardiovascular atendidos en un centro de salud de Barcelona

Cited by 41 publications

References 23 publications

SCORE and REGICOR function charts underestimate the cardiovascular risk in Spanish patients with rheumatoid arthritis

SCORE and REGICOR function charts underestimate the cardiovascular risk in Spanish patients with rheumatoid arthritis

Estimating Cardiovascular Risk in Spain by the European Guidelines on Cardiovascular Disease Prevention in Clinical Practice

Screening premorbid metabolic syndrome in community pharmacies: a cross-sectional descriptive study

Contact Info

Product

Resources

About